PSA-Cleavable Prodrug Peptide for Fast, Selective Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing prodrugs for targeting prostate cancer through prostate-specific antigen (PSA) cleavage face challenges in achieving rapid and selective activation while resisting cleavage by other enzymes, limiting their effectiveness in diagnosis and treatment.
Innovation Solution
A pro-moiety comprising a first peptide with a sequence that binds selectively to PSA and a second peptide with a negative charge to slow cellular uptake, designed to be rapidly cleaved by PSA, producing a conjugate suitable for cellular uptake.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If a prodrug is designed to be rapidly cleaved by PSA, then the activation speed is improved, but the selectivity against other enzymes deteriorates
Solution Approach 1:
The pro-moiety is divided into two distinct peptide sequences: a first sequence optimized for rapid PSA cleavage and a second sequence providing selective binding to PSA active site. This segmentation allows each component to fulfill its specific function - the first sequence ensures fast activation while the second ensures selectivity against other enzymes.
Solution Approach 2:
The pro-moiety combines two different peptide sequences with complementary functions into a single composite structure. The first peptide sequence provides rapid cleavability by PSA, while the second peptide sequence provides selective binding to PSA, creating a composite pro-moiety that achieves both speed and selectivity simultaneously.
2Reliability
If a prodrug uses a masking moiety that is cleaved by PSA, then the targeted drug delivery is improved, but the resistance to cleavage by other enzymes deteriorates
Solution Approach 1:
The second peptide sequence in the pro-moiety is specifically designed to interact with the active site of PSA, creating a localized binding region that provides selectivity. This local quality enhancement ensures that only PSA can efficiently cleave the prodrug, preventing off-target cleavage by other enzymes while maintaining targeted delivery to prostate cancer cells.
3Productivity
If the prodrug is designed for rapid cleavage, then the therapeutic efficacy is improved, but the stability against non-specific proteases deteriorates
Solution Approach 1:
The second peptide sequence is designed in advance to provide selective binding to PSA before cleavage occurs. This preliminary binding action ensures that the prodrug is protected from non-specific proteases until it reaches the target, where PSA is present in high concentrations. The pre-configured selective binding enhances therapeutic efficacy through rapid cleavage while maintaining stability against off-target enzymes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The pro-moiety enables rapid and selective activation of prodrugs by PSA, facilitating targeted drug delivery and uptake by prostate cancer cells, thereby enhancing diagnostic and therapeutic efficacy.
Implementation Method 1
configured at a second terminus to bind with high selectivity to the active site of PSA
Implementation Method 2
the second peptide is cleaved from the first peptide upon proteolysis by PSA to produce a conjugate of the first peptide and the drug
Implementation Method 3
the second peptide comprises a sequence having a negative charge to slow uptake of the prodrug by cells
Data Source
AI summary
A pro-moiety and a composition comprising a pro-moiety for use in a therapeutically or diagnostically effective amount in a method for detecting and/or treating prostate cancer in a subject is disclosed. The pro-moiety comprises a first peptide, and a second peptide that is linked to the first peptide, wherein the peptide comprises a sequence that is configured near a first terminus for conjugating to a drug to form a prodrug that is rapidly and/or highly selectively cleaved by prostate-specific antigen (PSA), and configured at a second terminus to bind with high selectivity to the active site of PSA, and the second peptide comprises a sequence having a negative charge to slow uptake of the prodrug by cells, and wherein the second peptide is cleaved from the first peptide upon proteolysis by PSA to produce a conjugate of the first peptide and the drug that is suitable for uptake by target cells.